53/120
2.2 / 5 stars
All 120 Win/Lose results shown below
SRPT Roast Me summary
Sarepta Therapeutics, Inc. (SRPT). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseSRPT / S&P -17.42% / 15.20% |
LoseSRPT / S&P -20.44% / 15.00% |
LoseSRPT / S&P SRPT unavailable / 50.40% |
| 2026-Q11/3 |
WinSRPT / S&P 1.12% / -4.33% |
LoseSRPT / S&P -2.20% / 11.30% |
LoseSRPT / S&P SRPT unavailable / 27.70% |
| 2025-Q42/3 |
WinSRPT / S&P 11.68% / 2.65% |
WinSRPT / S&P 15.58% / 9.00% |
LoseSRPT / S&P -404.70% / 13.40% |
| 2025-Q32/3 |
WinSRPT / S&P 12.69% / 8.12% |
WinSRPT / S&P 47.15% / 4.61% |
LoseSRPT / S&P -291.56% / 13.45% |
| 2025-Q21/3 |
LoseSRPT / S&P -73.21% / 10.94% |
WinSRPT / S&P 64.89% / 4.83% |
LoseSRPT / S&P -209.46% / 10.63% |
| 2025-Q11/3 |
LoseSRPT / S&P -47.51% / -4.27% |
WinSRPT / S&P 59.15% / 4.98% |
LoseSRPT / S&P -757.50% / 10.57% |
| 2024-Q41/3 |
LoseSRPT / S&P -2.64% / 2.41% |
WinSRPT / S&P 52.97% / 5.25% |
LoseSRPT / S&P SRPT unavailable / 6.15% |
| 2024-Q31/3 |
LoseSRPT / S&P -20.96% / 5.89% |
WinSRPT / S&P 48.45% / 5.89% |
LoseSRPT / S&P SRPT unavailable / 6.11% |
| 2024-Q22/3 |
WinSRPT / S&P 22.05% / 4.28% |
WinSRPT / S&P 49.98% / 5.38% |
LoseSRPT / S&P SRPT unavailable / 5.12% |
| 2024-Q12/3 |
WinSRPT / S&P 34.25% / 10.56% |
WinSRPT / S&P 43.83% / 5.71% |
LoseSRPT / S&P SRPT unavailable / 5.59% |
| 2023-Q41/3 |
LoseSRPT / S&P -20.45% / 11.69% |
WinSRPT / S&P 33.26% / 6.81% |
LoseSRPT / S&P SRPT unavailable / 7.78% |
| 2023-Q32/3 |
WinSRPT / S&P 5.85% / -3.27% |
WinSRPT / S&P 26.13% / 7.52% |
LoseSRPT / S&P SRPT unavailable / -5.03% |
| 2023-Q21/3 |
LoseSRPT / S&P -16.91% / 8.74% |
WinSRPT / S&P 20.15% / 9.50% |
LoseSRPT / S&P SRPT unavailable / -8.57% |
| 2023-Q11/3 |
LoseSRPT / S&P 6.37% / 7.50% |
WinSRPT / S&P 27.41% / 10.77% |
LoseSRPT / S&P SRPT unavailable / -15.69% |
| 2022-Q42/3 |
WinSRPT / S&P 17.22% / 7.56% |
WinSRPT / S&P 32.93% / 11.88% |
LoseSRPT / S&P SRPT unavailable / -17.99% |
| 2022-Q32/3 |
WinSRPT / S&P 47.47% / -4.88% |
WinSRPT / S&P 35.70% / 13.47% |
LoseSRPT / S&P SRPT unavailable / -1.41% |
| 2022-Q22/3 |
WinSRPT / S&P -4.05% / -16.10% |
WinSRPT / S&P 39.18% / 13.71% |
LoseSRPT / S&P SRPT unavailable / 11.04% |
| 2022-Q11/3 |
LoseSRPT / S&P -13.25% / -4.60% |
WinSRPT / S&P 33.56% / 15.97% |
LoseSRPT / S&P SRPT unavailable / 42.23% |
| 2021-Q41/3 |
LoseSRPT / S&P -2.63% / 11.03% |
WinSRPT / S&P 29.96% / 15.00% |
LoseSRPT / S&P SRPT unavailable / 96.40% |
| 2021-Q32/3 |
WinSRPT / S&P 18.96% / 0.58% |
WinSRPT / S&P 30.40% / 10.77% |
LoseSRPT / S&P SRPT unavailable / 69.42% |
| 2021-Q21/3 |
LoseSRPT / S&P 4.31% / 8.55% |
WinSRPT / S&P 33.29% / 6.58% |
LoseSRPT / S&P SRPT unavailable / 51.81% |
| 2021-Q11/3 |
LoseSRPT / S&P -56.28% / 6.17% |
WinSRPT / S&P 40.70% / -1.06% |
LoseSRPT / S&P SRPT unavailable / 7.39% |
| 2020-Q42/3 |
WinSRPT / S&P 21.41% / 12.15% |
WinSRPT / S&P 41.82% / -3.72% |
LoseSRPT / S&P SRPT unavailable / -33.42% |
| 2020-Q31/3 |
LoseSRPT / S&P -12.42% / 8.93% |
WinSRPT / S&P 35.59% / -2.04% |
LoseSRPT / S&P SRPT unavailable / -27.10% |
| 2020-Q22/3 |
WinSRPT / S&P 63.91% / 20.54% |
WinSRPT / S&P 30.65% / -0.46% |
LoseSRPT / S&P SRPT unavailable / -27.11% |
| 2020-Q11/3 |
LoseSRPT / S&P -24.19% / -19.60% |
WinSRPT / S&P 25.99% / 3.47% |
LoseSRPT / S&P SRPT unavailable / -14.75% |
| 2019-Q42/3 |
WinSRPT / S&P 71.32% / 9.07% |
WinSRPT / S&P 26.51% / 5.36% |
LoseSRPT / S&P SRPT unavailable / 2.99% |
| 2019-Q31/3 |
LoseSRPT / S&P -50.43% / 1.70% |
WinSRPT / S&P 33.31% / 5.02% |
LoseSRPT / S&P SRPT unavailable / 0.21% |
| 2019-Q22/3 |
WinSRPT / S&P 27.49% / 4.30% |
WinSRPT / S&P 42.76% / 6.64% |
LoseSRPT / S&P SRPT unavailable / 8.65% |
| 2019-Q11/3 |
LoseSRPT / S&P 9.22% / 13.65% |
WinSRPT / S&P 59.45% / 8.12% |
LoseSRPT / S&P SRPT unavailable / 14.29% |
| 2018-Q41/3 |
LoseSRPT / S&P -32.43% / -13.52% |
WinSRPT / S&P 94.74% / 9.05% |
LoseSRPT / S&P SRPT unavailable / 18.23% |
| 2018-Q31/3 |
WinSRPT / S&P 22.19% / 7.71% |
LoseSRPT / S&P SRPT unavailable / 10.21% |
LoseSRPT / S&P SRPT unavailable / 19.06% |
| 2018-Q21/3 |
WinSRPT / S&P 78.40% / 3.43% |
LoseSRPT / S&P SRPT unavailable / 9.03% |
LoseSRPT / S&P SRPT unavailable / 14.46% |
| 2018-Q11/3 |
WinSRPT / S&P 33.16% / -0.76% |
LoseSRPT / S&P SRPT unavailable / 7.68% |
LoseSRPT / S&P SRPT unavailable / 12.46% |
| 2017-Q42/3 |
WinSRPT / S&P 22.66% / 6.64% |
WinSRPT / S&P 2751.58% / 7.03% |
LoseSRPT / S&P SRPT unavailable / 13.82% |
| 2017-Q31/3 |
WinSRPT / S&P 34.56% / 4.48% |
LoseSRPT / S&P SRPT unavailable / 5.68% |
LoseSRPT / S&P SRPT unavailable / 17.57% |
| 2017-Q21/3 |
WinSRPT / S&P 13.89% / 3.09% |
LoseSRPT / S&P SRPT unavailable / 4.83% |
LoseSRPT / S&P SRPT unavailable / 17.74% |
| 2017-Q11/3 |
WinSRPT / S&P 7.91% / 6.07% |
LoseSRPT / S&P SRPT unavailable / 3.67% |
LoseSRPT / S&P SRPT unavailable / 13.32% |
| 2016-Q41/3 |
LoseSRPT / S&P -55.33% / 3.82% |
WinSRPT / S&P 332.64% / 2.09% |
LoseSRPT / S&P SRPT unavailable / 7.05% |
| 2016-Q31/3 |
WinSRPT / S&P 222.02% / 3.85% |
LoseSRPT / S&P SRPT unavailable / 0.20% |
LoseSRPT / S&P SRPT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | SRPT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 14.53% | 20.78% |
| Annualized return | 14.53% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | SRPT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -73.72% | 83.14% |
| Annualized return | -23.46% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | SRPT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -21.52% | 319.30% |
| Annualized return | -2.39% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |